IVERMECTIN has played a crucial role in the effective management of Covid 19 in Uttar Pradesh

Lucknow: The first World Ivermectin Day was launched in 2021 by Front Line Covid-19 Critical Care Alliance and raised massive awareness about the life-saving benefits of the medicine ivermectin, including for COVID-19 treatment and prevention. On considering the outstanding work of Dr. Surya Kant in the field of COVID-19 and Ivermectin, he has been conferred the membership of the prestigiousFront Line Covid-19 Critical Care Alliance as an international partner.

On the occasion of World Ivermectin day,2022, Dr. Surya Kant shared a glimpse of his vision and his vital work done on this wonder drug as a weapon against COVID-19.

Covid 19 Pandemic has affected humanity gravely for the last two and half years. Uttar Pradesh,the largest state of India with a population of 250 million has controlled Covid 19 very effectively and Ivermectin hasplayed a very dynamic role in the Treatment and Prevention of Covid. UP was the first State of India, which issuedIvermectin-based Government Order on 6th August2020 for the Treatment and Prevention of Covid. Dr. Surya Kant, who is a Professor and Head, of the Department of Respiratory Medicine at King George’s Medical University, UP Lucknow was an instrumental External Expert for the Committeefor framing this Government Order.Dr.Surya Kant and other experts of India published the world’s first and only White Paper on Ivermectin formed themain scientific basisfor this order.

According to the WHO-Coronavirus status as updated on 22nd July 2022: –

A total of 565, million confirmed cases including 6.3 million deaths are reported globally. In India, there have been 43 million confirmed cases with 5.25 lakh deaths till date. Reflecting on this number in Uttar Pradesh, which is the largest state in the nation a total of 2 million cases (4.5% of the total cases in India) and 23 thousand deaths (4.4% of total deaths in India) were reported (1). The relatively less fatality and cases of COVID-19 in Uttar Pradesh are largely attributed to the use of Ivermectin.

Ivermectin was discovered solely from a single micro-organism isolated at the “Kitasato Institute” in Tokyo, Japan from Japanese soil and the Japanese microbiologist Satoshi Ōmurawas behind it. William Campbell, thecollaborator at Merck Research Labs in New Jersey, tested their effect against parasitic worms affecting livestock and other animals. In 1981, it was 1st introduced commercially for use in animals. Later FDA approved it as the drug of choice for various parasitic diseases in humans and animals, namelyonchocerciasis, strongyloidiasis, head lice, scabies, trichuriasis, ascariasis, filariasis, loa loa filariasis, and rosacea (inflammatory acne). In 2015 Ōmura & Campbell won the Nobel prizein physiology/medicine for discovering this wonderful drug (2).

Ivermectin was commercialized in 1981. Ivermectin is economical, easily available, safe and is a well-tolerated drug, and does not have any significant drug-to-drug interaction. In 2019, Ivermectin was included in the 21st WHO’s List of Essential Medicines. (3,4).

Ivermectin exerts broad-spectrum antiviral activity against several animal and human viruses, including both RNA and DNA viruses.The antiviral potential of ivermectin against various viruses is mediated through complex mechanisms involving inhibition of the nuclear trafficking of the virus.

Dr. Surya Kant has publishedresearch articles on Ivermectin in various medical journals of repute.Dr. Surya Kant also facilitated the free distribution of ivermectin based medicine for the treatment and prevention of COVID-19 in rural and remote areas with the help of various NGOs. He also advocated,trained , sensitized and popularized the ivermectin based treatment protocol of COVID 19 via lectures, seminars, webinars and through electronic and print media

नोट: अगर आपको यह खबर पसंद आई तो इसे शेयर करना न भूलें, देश-विदेश से जुड़ी ताजा अपडेट पाने के लिए कृपया The Lucknow Tribune के  Facebook  पेज को Like व Twitter पर Follow करना न भूलें... ------------------------- ------------------------------------------------------ -------------------------------------------------------- ------------------------------------------------------------------- --------------------------------------------- --------------------------------------------------------------- --------------------------------------------------------- --------------------------------------------------------------------------   ----------------------------------------------------------- -------------------------------------------------- -----------------------------------------------------------------------------------------
----------- -------------------------------------------------------------------------------------------------------------------------------------------------
E-Paper